News | December 09, 2014

University of Pennsylvania Doses First Patient Using CardioCell’s Stem Cell Therapy for Heart Failure

The Only Chronic HF Clinical Trial Using Ischemia-Tolerant Mesenchymal Stem Cells (itMSCs) Continues Recruitment at Emory University, Northwestern University and the University of Pennsylvania

Stem cell therapies, heart failure, bone marrow cells, clinical trial

Image courtesy of Miami University Miller School of Medicine

December 9, 2014 — CardioCell LLC announced the treatment of its first patient in the University of Pennsylvania’s Phase IIa clinical trial for chronic heart failure (HF) of non-ischemic cardiomyopathy. The trial, “Single-blind, Placebo-controlled, Crossover, Multi-center, Randomized Study to Assess the Safety, Tolerability and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Heart Failure of Non-ischemic Etiology,” is recruiting 20 eligible patients from three sites – Emory University, Northwestern University and the University of Pennsylvania.

Non-ischemic chronic HF is characterized by a viable but non-functioning myocardium in which cardiomyocytes are alive but are not contracting as they should. CardioCell’s therapy uses itMSCs that secrete large numbers of cytokines and growth factors, and this study will test if their unique properties will transition patients’ cardiomyocytes from viable to functioning, eventually restoring or improving heart function.

Chronic HF represents the single largest cause of natural death in the United States. Approximately 5.5 million individuals suffer from chronic HF, and it generates more than 1 million hospitalizations annually, with a 50-percent mortality and re-admission rate after 60-90 days post-discharge. About 35 percent of chronic HF patients suffer from abnormal heart function not related to coronary artery disease. In these cases the heart weakens and enlarges, preventing the efficient pumping of blood to the lungs, liver and other systems. This study is designed to test if itMSC treatment via intravenous injection can show efficacy in these patients with non-ischemic cardiomyopathy.

The Phase IIa clinical trial divides half of the patients into a treatment group and the other half into a control group. CardioCell’s treatment and the placebo are administered intravenously. Progress is tracked at the baseline, at 90 days and at 180 days. MRI measurements are used to capture improvements in ejection fraction (EF) and segmental changes in contractility. At 90 days after the first injection, the control group receives CardioCell’s treatment, and the previous treatment group will become the control group receiving saline solution. Thus, all the participants will receive treatment. The endpoint includes EF measurements every three months to observe signs of efficacy.

Only CardioCell’s chronic HF therapies feature itMSCs, which are licensed from CardioCell’s parent company Stemedica. Unlike all other MSCs – which are grown under normoxic conditions – Stemedica’s bone-marrow-derived, allogeneic itMSCs are unique because they are grown under hypoxic conditions. In vitro experiments demonstrate cells that are exposed to hypoxic conditions show greater homing and engraftment than cells grown under normoxic conditions. Compared to other MSCs, itMSCs secrete higher levels of growth factors and other important proteins associated with neoangiogenesis and healing.

For more information:


Related Content

Secant Introduces First Synthetic Regenerative Cardiovascular Graft for CABG
News | Stem Cell Therapies | January 17, 2018
Secant Group, in partnership with its sister company SanaVita Medical, announced new technology to advance...
News | Stem Cell Therapies | October 24, 2017
October 24, 2017 — Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate compani
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies | September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies | August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...

An example of porcine cartdiac stem cells. Photo from the University of Miami Miller School of Medicine.


News | Stem Cell Therapies | June 12, 2017
June 12, 2017 — Heart muscle is one of the least renewable tissues in the body, which is one of the reasons that hear
Stem Cell Therapy Holds Promise for Treating Most Severe Cases of Angina
News | Stem Cell Therapies | May 12, 2017
An analysis of data from the entire development program consisting of three trials assessing the feasibility of using a...
3-D Printed Patch Can Help Mend a ‘Broken’ Heart

This photo shows the 3D-bioprinted cell patch in comparison to a mouse heart. When the patch was placed on a live mouse following a simulated heart attack, the researchers saw significant increase in functional capacity after just four weeks. Image courtesy of Patrick O’Leary, University of Minnesota.

News | Stem Cell Therapies | April 18, 2017
April 18, 2017 — A team of biomedical engineering researchers, led by the University of Minnesota, has created a revo
Texas Heart Institute, ischemic heart failure, adult stem cell therapy, CONCERT-HF clinical trial
News | Stem Cell Therapies | February 03, 2017
Physicians and researchers at Texas Heart Institute are recruiting patients who suffer from heart failure to...
News | Stem Cell Therapies | January 09, 2017
BioCardia Inc. announced in December the issuance of United States Patent No. 9,517,199 relating to a method of...
Overlay Init